Accessibility Menu
Arrow-Thin-Down
S&P 500
6,738.44
+0.6%
+39.04
Arrow-Thin-Down
DJI
46,734.61
+0.3%
+144.20
Arrow-Thin-Down
NASDAQ
22,941.80
+0.9%
+201.40
Arrow-Thin-Down
Bitcoin
$110,506
+1.8%
+$1,956.76
Arrow-Thin-Down
AAPL
$259.44
+0.4%
+$0.99
Arrow-Thin-Down
AMZN
$221.02
+1.4%
+$3.07
Arrow-Thin-Down
GOOG
$253.73
+0.5%
+$1.2
Arrow-Thin-Down
META
$734.15
+0.1%
+$0.74
Arrow-Thin-Down
MSFT
$520.56
+0.0%
+$0.02
Arrow-Thin-Down
NVDA
$182.2
+1.1%
+$1.92
Arrow-Thin-Down
TSLA
$448.95
+2.3%
+$9.98
Daily Stock GainersDaily Stock LosersMost Active Stocks
Acumen Pharmaceuticals Stock Quote

Acumen Pharmaceuticals (NASDAQ: ABOS)

$2.11
(14.1%)
+0.26
Price as of October 23, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$2.11
Daily Change
(14.1%) +$0.26
Day's Range
$1.9 - $2.15
Previous Close
$2.11
Open
$1.9
Beta
0
Volume
442,800
Average Volume
337,036
Sector
Health Care
Market Cap
112.1M
Market Cap / Employee
$1.85M
52wk Range
$0.86 - $3.36
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$2.27
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Acumen Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ABOS-33.93%N/AN/A-91%
S&P+16.23%+94.45%+14.22%+56%

Acumen Pharmaceuticals Company Info

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

News & Analysis

Featured Article

Why Shares of Acumen Pharmaceuticals Are Down Tuesday

The company announced a $100 million stock sale.

James Halley  |  Jul 18, 2023

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.05M-4.4%
Market Cap$70.27M-51.7%
Market Cap / Employee$1.15M0.0%
Employees6117.3%
Net Income-$40.95M-99.4%
EBITDA-$41.70M-71.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$36.81M-45.8%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$29.96M1.2%
Short Term Debt$0.14M13.6%

Ratios

Q2 2025YOY Change
Return On Assets-59.32%-31.5%
Return On Invested Capital-30.53%16.8%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$31.84M-92.4%
Operating Free Cash Flow-$31.83M-92.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.610.480.360.45-18.58%
Price to Tangible Book Value0.610.480.360.45-18.58%
Enterprise Value to EBITDA0.660.971.741.03-70.60%
Return on Equity-32.8%-45.6%-55.7%-75.7%140.92%
Total Debt$29.99M$29.70M$29.78M$30.10M1.27%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services